Bionor’s product pipeline consists of three products which are the backbone of the Functional HIV Cure strategy.
The 3 product candidates Vacc-4x, Vacc-C5 and Vacc-CRX serves different functions in this strategy.
- Vacc-4x is a T-cell vaccine candidate that targets the conserved structural parts of the capsid protein of HIV, thereby killing HIV infected cells by Cytotoxic T-cell Lymphocytes (CTL) and reducing HIV reservoirs.
- Vacc-C5 is an antibody vaccine candidate that targets the 5th conserved domain on the envelope protein. Due to its conserved nature, Vacc-C5 antibodies effectively bind and block the biological function of this domain. These antibodies can kill HIV infected cells via Antibody Dependent Cell Cytotoxicity (ADCC) leading to further reduction of HIV reservoirs.
- Vacc-CRX interferes with the binding between HIV and the cell co-receptor(s) CCR5/CXCR4 thereby preventing HIV from entering CD4 cells.
The functional HIV Cure based on this therapeutic vaccine combination aims to reduce viral reservoirs and at the same time induce full viral load control via the entry-inhibiting properties of Vacc-CRX. A continuous exposure of HIV and HIV infected cells to CTL and ADCC without reinfection of new CD4 cells will lead to a steady depletion of HIV reservoirs over time. This is in contrast to ART, which only to a limited degree allows for exposure of HIV and HIV infected cells leaving the reservoirs unchanged. Our research suggests that our 3 product candidates combined will have the potential to produce a true Functional HIV Cure.